Annual Report

Overview

The report covers FY2023 performance for CLINUVEL's diversified pharmaceutical group. Its ESG feature reports 43% female representation on the Board, no breaches of the Code of Conduct or whistleblower reports, and one minor injury with no time lost. Governance reporting to the Board was formalised monthly, while a formal ESG review process for the 25 largest suppliers was finalised and became effective 1 July 2023.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2023
Period: Ends 30 June 2023
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services